The vaccine has a 94.1% efficacy rate against COVID-19.
Messenger RNA-pioneering biotechnology company Moderna has announced that it has secured an agreement with Singapore’s Ministry of Health to supply the country with Moderna’s vaccine candidate against COVID-19, mRNA-1273.
“We continue to advance the clinical development of mRNA-1273 and the recent positive primary efficacy analysis from our Phase 3 COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world,” said Moderna’s CEO Stéphane Bancel in a statement.
Data from the Phase COVE study, which involved 30,000 participants, has shown an efficacy rate against COVID-19 at 94.1% and against severe COVID-19 at 100%. “Efficacy was consistent across age, race and ethnicity, and gender demographics in the 196 observed cases of COVID-19,” Moderna noted.